|
|
| (29 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| {{Argatroban}} | | |valign=top| |
| {{CMG}}; {{AE}} {{JH}}
| | |+ |
| | | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| ==Overview== | | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| '''Argatroban''' is an [[anticoagulant]] that is a small molecule [[direct thrombin inhibitor]]. In 2000, argatroban was licensed by the [[Food and Drug Administration]] (FDA) for prophylaxis or treatment of [[thrombosis]] in patients with [[heparin-induced thrombocytopenia|heparin-induced thrombocytopenia (HIT)]]. In 2002, it was approved for use during [[Angioplasty|percutaneous coronary interventions]] in patients who have or at risk for developing [[HIT]].
| | |- |
| | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| Argatroban is given intravenously. Argatroban is metabolized in the [[liver]] and has a half life of about 50 minutes. It is monitored by [[PTT]]. Because of its hepatic metabolism, it may be used in patients with [[renal dysfunction]]. (This is in contrast to [[lepirudin]], a [[direct thrombin inhibitor]] that is primarily renally cleared).
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| It is manufactured by [[GlaxoSmithKline]].
| | |} |
| | |
| ==Category== | |
| | |
| Anticoagulants; Direct Thrombin Inhibitor
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ====ARGATROBAN injection, solution====
| |
| | |
| ''' [[Argatroban indications and usage|Indications and Usage]]'''
| |
| '''| [[Argatroban dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Argatroban dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Argatroban contraindications|Contraindications]]'''
| |
| '''| [[Argatroban warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Argatroban adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Argatroban drug interactions|Drug Interactions]]'''
| |
| '''| [[Argatroban use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Argatroban overdosage|Overdosage]]'''
| |
| '''| [[Argatroban description|Description]]'''
| |
| '''| [[Argatroban clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Argatroban nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Argatroban clinical studies|Clinical Studies]]'''
| |
| '''| [[Argatroban how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Argatroban patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Argatroban labels and packages|Labels and Packages]]'''
| |
| | |
| ==Reference== | |
| | |
| * Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. ''[[N Engl J Med]]'' 2005;353:1028-40. PMID 16148288.
| |
| | |
| ==External links==
| |
| | |
| *[http://www.argatroban.com GlaxoSmithKline's website on argatroban]
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiology]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| [[Category:Hematology]]
| |